Xingxing Chen1, Xuehua Lin1, Guofu Pang1, Jian Deng1, Qun Xie1, Zhengrong Zhang2. 1. Department of Urology, Zhuhai People's Hospital, Zhuhai Hospital affiliated with Jinan University, Kangning Road No.79, in Zhuhai city, Guang Dong Province, Zhuhai, People's Republic of China. 2. Department of Urology, Zhuhai People's Hospital, Zhuhai Hospital affiliated with Jinan University, Kangning Road No.79, in Zhuhai city, Guang Dong Province, Zhuhai, People's Republic of China. 76240500@qq.com.
Abstract
BACKGROUND: Bladder cancer (BC) is the fourth most prevalent neoplasm in men and is associated with high tumour recurrence rates, leading to major treatment challenges. Lysine-specific demethylase 6A (KDM6A) is frequently mutated in several cancer types; however, its effects on tumour progression and clinical outcome in BC remain unclear. Here, we explored the potential role of KDM6A in regulating the antitumor immune response. METHODS: We mined The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases for somatic mutation and clinical data in patients with BC. RESULTS: We found frequent mutations in 12 genes in both cohorts, including TP53, KDM6A, CSMD3, MUC16, STAG2, PIK3CA, ARID1A, RB1, EP300, ERBB2, ERBB3, and FGFR3. The frequency o KDM6A mutations in the TCGA and ICGC datasets was 25.97 and 24.27%, respectively. In addition, KDM6A mutation was associated with a lower number of tumour-infiltrating immune cells (TIICs) and indicated a state of immune tolerance. KDM6A mutation was associated with lower KDM6A mRNA level compared with that in samples carrying the wild-type gene. Further, survival analysis showed that the prognosis of patients with low KDM6A expression was worse than that with high KDM6A expression. Using the CIBERSORT algorithm, Tumor Immune Estimation Resource site, and Gene Set Enrichment Analysis, we found that KDM6A mutation downregulated nine signalling pathways that participate in the immune system and attenuated the tumour immune response. CONCLUSION: Overall, we conclude that KDM6A mutation is frequent in BC and promotes tumour immune escape, which may serve as a novel biomarker to predict the immune response.
BACKGROUND:Bladder cancer (BC) is the fourth most prevalent neoplasm in men and is associated with high tumour recurrence rates, leading to major treatment challenges. Lysine-specific demethylase 6A (KDM6A) is frequently mutated in several cancer types; however, its effects on tumour progression and clinical outcome in BC remain unclear. Here, we explored the potential role of KDM6A in regulating the antitumor immune response. METHODS: We mined The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases for somatic mutation and clinical data in patients with BC. RESULTS: We found frequent mutations in 12 genes in both cohorts, including TP53, KDM6A, CSMD3, MUC16, STAG2, PIK3CA, ARID1A, RB1, EP300, ERBB2, ERBB3, and FGFR3. The frequency o KDM6A mutations in the TCGA and ICGC datasets was 25.97 and 24.27%, respectively. In addition, KDM6A mutation was associated with a lower number of tumour-infiltrating immune cells (TIICs) and indicated a state of immune tolerance. KDM6A mutation was associated with lower KDM6A mRNA level compared with that in samples carrying the wild-type gene. Further, survival analysis showed that the prognosis of patients with low KDM6A expression was worse than that with high KDM6A expression. Using the CIBERSORT algorithm, Tumor Immune Estimation Resource site, and Gene Set Enrichment Analysis, we found that KDM6A mutation downregulated nine signalling pathways that participate in the immune system and attenuated the tumour immune response. CONCLUSION: Overall, we conclude that KDM6A mutation is frequent in BC and promotes tumour immune escape, which may serve as a novel biomarker to predict the immune response.
Authors: Yongkun Wei; Weiya Xia; Zhihong Zhang; Jinsong Liu; Huamin Wang; Nazmi V Adsay; Constance Albarracin; Dihua Yu; James L Abbruzzese; Gordon B Mills; Robert C Bast; Gabriel N Hortobagyi; Mien-Chie Hung Journal: Mol Carcinog Date: 2008-09 Impact factor: 4.784
Authors: Jinfeng Liu; William Lee; Zhaoshi Jiang; Zhongqiang Chen; Suchit Jhunjhunwala; Peter M Haverty; Florian Gnad; Yinghui Guan; Houston N Gilbert; Jeremy Stinson; Christiaan Klijn; Joseph Guillory; Deepali Bhatt; Steffan Vartanian; Kimberly Walter; Jocelyn Chan; Thomas Holcomb; Peter Dijkgraaf; Stephanie Johnson; Julie Koeman; John D Minna; Adi F Gazdar; Howard M Stern; Klaus P Hoeflich; Thomas D Wu; Jeff Settleman; Frederic J de Sauvage; Robert C Gentleman; Richard M Neve; David Stokoe; Zora Modrusan; Somasekar Seshagiri; David S Shames; Zemin Zhang Journal: Genome Res Date: 2012-10-02 Impact factor: 9.043
Authors: Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding Journal: Nature Date: 2013-10-17 Impact factor: 49.962